Cargando…

Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format

Background: The COVID-19 pandemic has brought to light both challenges and unique opportunities regarding type 1 diabetes (T1D) management, including the usage of telemedicine platforms. Methods: This study was conducted in a tertiary hospital diabetes clinic. All consecutive T1D patients during Mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiller, Tal, Zornitzki, Taiba, Ostrovsky, Viviana, Sapojnik, Danielle, Cohen, Lee, Kunyavski, Tamila, Knobler, Hilla, Kirzhner, Alena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583150/
https://www.ncbi.nlm.nih.gov/pubmed/34769826
http://dx.doi.org/10.3390/ijerph182111309
_version_ 1784597147991146496
author Schiller, Tal
Zornitzki, Taiba
Ostrovsky, Viviana
Sapojnik, Danielle
Cohen, Lee
Kunyavski, Tamila
Knobler, Hilla
Kirzhner, Alena
author_facet Schiller, Tal
Zornitzki, Taiba
Ostrovsky, Viviana
Sapojnik, Danielle
Cohen, Lee
Kunyavski, Tamila
Knobler, Hilla
Kirzhner, Alena
author_sort Schiller, Tal
collection PubMed
description Background: The COVID-19 pandemic has brought to light both challenges and unique opportunities regarding type 1 diabetes (T1D) management, including the usage of telemedicine platforms. Methods: This study was conducted in a tertiary hospital diabetes clinic. All consecutive T1D patients during March and June 2021 were asked to fill out a structured anonymous questionnaire that aimed to determine their preference regarding continuous use of a virtual platform. Results: In total, 126 T1D patients answered the questionnaire, of whom 51% were under the age of 40, half were men, half used insulin pumps, and 69% used continuous glucose monitoring. During the pandemic, the exposure of patients to virtual visits has grown about twofold, from 29% to 53%. Of the respondents, 49% expressed an interest in future usage of a virtual platform, but most of them preferred use in a hybrid manner. We found an association between preference to use telemedicine in the future and younger age, previous virtual platform experience, and confidence in being able to download data. Conclusions: Our data demonstrate that the COVID-19 experience has led to a growing interest of T1D patients in using the hybrid format of telemedicine. However, we still need to better understand who will benefit most from this platform and assess its cost-effectiveness and organization.
format Online
Article
Text
id pubmed-8583150
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85831502021-11-12 Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format Schiller, Tal Zornitzki, Taiba Ostrovsky, Viviana Sapojnik, Danielle Cohen, Lee Kunyavski, Tamila Knobler, Hilla Kirzhner, Alena Int J Environ Res Public Health Article Background: The COVID-19 pandemic has brought to light both challenges and unique opportunities regarding type 1 diabetes (T1D) management, including the usage of telemedicine platforms. Methods: This study was conducted in a tertiary hospital diabetes clinic. All consecutive T1D patients during March and June 2021 were asked to fill out a structured anonymous questionnaire that aimed to determine their preference regarding continuous use of a virtual platform. Results: In total, 126 T1D patients answered the questionnaire, of whom 51% were under the age of 40, half were men, half used insulin pumps, and 69% used continuous glucose monitoring. During the pandemic, the exposure of patients to virtual visits has grown about twofold, from 29% to 53%. Of the respondents, 49% expressed an interest in future usage of a virtual platform, but most of them preferred use in a hybrid manner. We found an association between preference to use telemedicine in the future and younger age, previous virtual platform experience, and confidence in being able to download data. Conclusions: Our data demonstrate that the COVID-19 experience has led to a growing interest of T1D patients in using the hybrid format of telemedicine. However, we still need to better understand who will benefit most from this platform and assess its cost-effectiveness and organization. MDPI 2021-10-28 /pmc/articles/PMC8583150/ /pubmed/34769826 http://dx.doi.org/10.3390/ijerph182111309 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schiller, Tal
Zornitzki, Taiba
Ostrovsky, Viviana
Sapojnik, Danielle
Cohen, Lee
Kunyavski, Tamila
Knobler, Hilla
Kirzhner, Alena
Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format
title Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format
title_full Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format
title_fullStr Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format
title_full_unstemmed Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format
title_short Following the COVID-19 Experience, Many Patients with Type 1 Diabetes Wish to Use Telemedicine in a Hybrid Format
title_sort following the covid-19 experience, many patients with type 1 diabetes wish to use telemedicine in a hybrid format
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583150/
https://www.ncbi.nlm.nih.gov/pubmed/34769826
http://dx.doi.org/10.3390/ijerph182111309
work_keys_str_mv AT schillertal followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat
AT zornitzkitaiba followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat
AT ostrovskyviviana followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat
AT sapojnikdanielle followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat
AT cohenlee followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat
AT kunyavskitamila followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat
AT knoblerhilla followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat
AT kirzhneralena followingthecovid19experiencemanypatientswithtype1diabeteswishtousetelemedicineinahybridformat